Skip to main content
Journal cover image

Postmarket evaluation of breakthrough technologies.

Publication ,  Journal Article
Rao, SV; Califf, RM; Kramer, JM; Peterson, ED; Gross, TP; Pepine, CJ; Williams, DO; Donohoe, D; Waksman, R; Mehran, R; Krucoff, MW
Published in: Am Heart J
August 2008

Cardiovascular procedures performed in the United States have more than tripled in the last decade, a trend that is expected to continue with the aging of the population, coupled with epidemics of obesity and diabetes mellitus. Helping to drive this increase are new medical devices that address conditions previously treated by medication alone. Many of these novel devices receive expedited reviews before Food and Drug Administration (FDA) approval and are rapidly adopted into clinical practice. However, recent high-profile cases involving potentially dangerous defects in widely used medical devices have increased concerns about the adequacy of premarket trials and postmarket surveillance in establishing the safety of these devices. In response to these concerns, the American College of Cardiology and the Duke Clinical Research Institute sponsored a "think tank" of experts representing the industry, regulatory authorities, academic medicine, and professional societies to examine these concerns and propose possible solutions. This group examined case studies including drug-eluting stents and implantable cardioverter-defibrillators. Challenges inherent in the current system, including the difficulty of establishing accurate event rates for medical devices and potential disincentives for the industry to conduct comprehensive monitoring, were discussed. Possible solutions to these problems included improving and enforcing current regulations, considering creative study design strategies that link pre- and postmarket data, declaring postmarket surveillance a public health issue, creating financial incentives for participation in postmarketing studies, using more relevant animal models, encouraging postmortem device retrieval, and aligning professional societies with the FDA to evaluate breakthrough technologies and communicate findings to patients and clinicians.

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

August 2008

Volume

156

Issue

2

Start / End Page

201 / 208

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Product Surveillance, Postmarketing
  • Models, Animal
  • Industry
  • Humans
  • Government Regulation
  • Equipment Safety
  • Equipment Failure
  • Drug-Eluting Stents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rao, S. V., Califf, R. M., Kramer, J. M., Peterson, E. D., Gross, T. P., Pepine, C. J., … Krucoff, M. W. (2008). Postmarket evaluation of breakthrough technologies. Am Heart J, 156(2), 201–208. https://doi.org/10.1016/j.ahj.2008.01.036
Rao, Sunil V., Robert M. Califf, Judith M. Kramer, Eric D. Peterson, Thomas P. Gross, Carl J. Pepine, David O. Williams, et al. “Postmarket evaluation of breakthrough technologies.Am Heart J 156, no. 2 (August 2008): 201–8. https://doi.org/10.1016/j.ahj.2008.01.036.
Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, et al. Postmarket evaluation of breakthrough technologies. Am Heart J. 2008 Aug;156(2):201–8.
Rao, Sunil V., et al. “Postmarket evaluation of breakthrough technologies.Am Heart J, vol. 156, no. 2, Aug. 2008, pp. 201–08. Pubmed, doi:10.1016/j.ahj.2008.01.036.
Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, Krucoff MW. Postmarket evaluation of breakthrough technologies. Am Heart J. 2008 Aug;156(2):201–208.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

August 2008

Volume

156

Issue

2

Start / End Page

201 / 208

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Product Surveillance, Postmarketing
  • Models, Animal
  • Industry
  • Humans
  • Government Regulation
  • Equipment Safety
  • Equipment Failure
  • Drug-Eluting Stents